Pages that link to "Q24303965"

The following pages link to The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR (Q24303965):

Displaying 50 items.

• Low density lipoprotein receptor (Q425649) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 9 (Q21130010) ‎ (← links)
• A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo (Q21136366) ‎ (← links)
• Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation (Q24294486) ‎ (← links)
• Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH (Q24297165) ‎ (← links)
• The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2 (Q24301411) ‎ (← links)
• Self-association of human PCSK9 correlates with its LDLR-degrading activity (Q24306591) ‎ (← links)
• Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9) (Q24312859) ‎ (← links)
• Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels (Q24313575) ‎ (← links)
• The PCSK9 decade (Q24615397) ‎ (← links)
• PCSK9 and triglyceride-rich lipoprotein metabolism (Q26796287) ‎ (← links)
• Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain (Q27339783) ‎ (← links)
• The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain (Q27647905) ‎ (← links)
• Molecular basis for LDL receptor recognition by PCSK9 (Q27649779) ‎ (← links)
• Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells (Q27653836) ‎ (← links)
• PCSK9 inhibitors in the prevention of cardiovascular disease (Q28071452) ‎ (← links)
• New Era of Lipid-Lowering Drugs (Q28072298) ‎ (← links)
• Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor (Q28258969) ‎ (← links)
• Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells (Q28304381) ‎ (← links)
• In vivo evidence that furin from hepatocytes inactivates PCSK9 (Q28504537) ‎ (← links)
• Evidence for positive selection in the C-terminal domain of the cholesterol metabolism gene PCSK9 based on phylogenetic analysis in 14 primate species (Q28756853) ‎ (← links)
• SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion (Q29347035) ‎ (← links)
• IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor (Q30538763) ‎ (← links)
• The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions (Q30541820) ‎ (← links)
• A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake (Q33532964) ‎ (← links)
• Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease (Q33599961) ‎ (← links)
• Identifying low density lipoprotein cholesterol associated variants in the Annexin A2 (ANXA2) gene (Q33732407) ‎ (← links)
• What lies ahead for the proprotein convertases? (Q34169463) ‎ (← links)
• Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein (Q34227474) ‎ (← links)
• The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis (Q34355679) ‎ (← links)
• PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges (Q34424500) ‎ (← links)
• Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs (Q34430377) ‎ (← links)
• Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men (Q34560789) ‎ (← links)
• A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor (Q34568486) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1) (Q34723257) ‎ (← links)
• PCSK9 prosegment chimera as novel inhibitors of LDLR degradation (Q34951227) ‎ (← links)
• Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists (Q35096270) ‎ (← links)
• Comparative analysis of human tissue interactomes reveals factors leading to tissue-specific manifestation of hereditary diseases (Q35186314) ‎ (← links)
• Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function (Q35612555) ‎ (← links)
• Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9 (Q35879455) ‎ (← links)
• Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other (Q35883857) ‎ (← links)
• Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. (Q36281706) ‎ (← links)
• Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial (Q36410111) ‎ (← links)
• Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver (Q36520700) ‎ (← links)
• Plasma PCSK9 preferentially reduces liver LDL receptors in mice (Q36662650) ‎ (← links)
• Plasma PCSK9 levels are significantly modified by statins and fibrates in humans (Q36728777) ‎ (← links)
• The proprotein convertases are potential targets in the treatment of dyslipidemia (Q36757387) ‎ (← links)
• Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations (Q36866980) ‎ (← links)
• Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels (Q37348178) ‎ (← links)
• Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. (Q37384902) ‎ (← links)